Please confirm you are human (Sign Up for free to never see this)
← Back to Search
Factors Influencing Initial Choice Of Insulin Therapy In A Large International Non-interventional Study Of People With Type 2 Diabetes
N. Freemantle, B. Balkau, N. Danchin, E. Wang, M. Marre, G. Vespasiani, R. Kawamori, P. Home
Published 2012 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
Aim: To use baseline characteristics of the Cardiovascular Risk Evaluation in people with type 2 Diabetes on Insulin Therapy study population to identify factors that could explain the choice of insulin therapy when beginning insulin.
This paper references
How Doctors Choose Medications to Treat Type 2 Diabetes
R. Grant (2007)
Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study.
M. Peyrot (2005)
Study design and baseline characteristics of patients in the PRESENT study.
M. Shestakova (2008)
Present status of sulfonylurea treatment for type 2 diabetes in Japan: second report of a cross-sectional survey of 15,652 patients.
K. Arai (2010)
10-year follow-up of intensive glucose control in type 2 diabetes.
R. Holman (2008)
International Diabetes Federation. IDF Clinical Guidelines Task Force. Global guideline for Type 2 diabetes. Brussels: Brussels International Diabetes Federation
New insulins and new insulin regimens: a review of their role in improving glycaemic control in patients with diabetes
W. Crasto (2009)
The IMPROVE™ study – a multinational, observational study in type 2 diabetes: baseline characteristics from eight national cohorts
P. Valensi (2008)
American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus.
H. Rodbard (2007)
Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials
K. Ray (2009)
Heterogeneous relationship of early insulin response and fasting insulin level with development of non-insulin-dependent diabetes mellitus in non-diabetic Japanese subjects with or without obesity.
H. Yoshinaga (1999)
The burden of treatment failure in type 2 diabetes.
J. Brown (2004)
Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy
D. Nathan (2008)
0] 8.2 (1.6) [7.9, 8.6] 9.8 (2.0) [9.6, 9.9] 8.8 (1.7) [8
Importance of observational studies in clinical practice.
R. Ligthelm (2007)
Intensive glucose control and macrovascular outcomes in type 2 diabetes
F. Turnbull (2009)
This paper is referenced by
OptiMising therapy after MetfOrMin in type 2 diabetes
R. Moore (2015)
High level of clinical inertia in insulin initiation in type 2 diabetes across Central and South-Eastern Europe: insights from SITIP study
Matthew D. Campbell (2019)
O R I G I N a L I N V E S T I G a T I O N Open Access
Ryuzo Kawamori ()
Outcomes of transition from premixed and intensive insulin therapies to insulin aspart/degludec co-formulation in type 2 diabetes mellitus: a real-world experience
Serhat Ozcelik (2020)
Factors Associated With Weight Gain in People With Type 2 Diabetes Starting on Insulin
B. Balkau (2014)
Relationship of glycaemic control and hypoglycaemic episodes to 4‐year cardiovascular outcomes in people with type 2 diabetes starting insulin
N. Freemantle (2016)
Fighting type-2 diabetes: present and future perspectives.
Cai-Guo Yu (2017)
Predictors of HbA1c over 4 years in people with type 2 diabetes starting insulin therapies: The CREDIT study.
B. Balkau (2015)
Efficacy and safety of premixed insulin analogs in Asian patients with type 2 diabetes: A systematic review
W. Sheu (2017)
Four-year evolution of insulin regimens, glycaemic control, hypoglycaemia and body weight after starting insulin therapy in type 2 diabetes across three continents.
P. Home (2015)
Le diabète de type 2 au stade de l’insuline : Quelle place pour les inhibiteurs de la DPP-4 ?
S. Halimi (2015)
A propensity score matched comparison of different insulin regimens 1 year after beginning insulin in people with type 2 diabetes
N. Freemantle (2013)
Efficacy and safety of empagliflozin as add‐on to insulin in Japanese patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled trial
H. Sone (2019)
Switching From Insulin Bolus Treatment to GLP-1 RAs Added to Continued Basal Insulin in People With Type 2 Diabetes on Basal-Bolus Insulin
G. Bolli (2020)
Clinical correlates of hypoglycaemia over 4 years in people with type 2 diabetes starting insulin: An analysis from the CREDIT study
P. Home (2018)
Insulin lispro 25/75 and insulin lispro 50/50 as starter insulin in Japanese patients with type 2 diabetes: subanalysis of the CLASSIFY randomized trial.
H. Watada (2017)
Twice-daily insulin degludec/insulin aspart effectively improved morning and evening glucose levels and quality of life in patients previously treated with premixed insulin: an observational study
Kanta Fujimoto (2018)
Baseline and 1-year interim follow-up assessment of Japanese patients initiating insulin therapy who were enrolled in the cardiovascular risk evaluation in people with type 2 diabetes on insulin therapy study: an international, multicenter, observational study
R. Kawamori (2013)
Influence of Patient Characteristics on The Type of Insulin Therapy Obtained by Diabetes Type 2 Outpatient in Denpasar Municipality
L. P. F. Larasanty (2017)
Blood glucose profiles in East Asian and Caucasian injection‐naive patients with type 2 diabetes inadequately controlled on oral medication: a pooled analysis
X. Zhang (2018)
Comparison of insulin lispro mix 25 with insulin lispro mix 50 as an insulin starter in Asian patients with type 2 diabetes: a phase 4, open‐label, randomized trial (CLASSIFY study)
H. Watada (2017)
Effectiveness and safety of basal supported oral therapy with insulin glargine, in Japanese insulin-naive, type 2 diabetes patients, with or without microvascular complications: subanalysis of the observational, non-interventional, 24-week follow-up Add-on Lantus® to Oral Hypoglycemic Agents (ALOHA)
M. Odawara (2015)
Towards an improved global understanding of treatment and outcomes in people with type 2 diabetes: Rationale and methods of the DISCOVER observational study program.
L. Ji (2017)
Utilization patterns of insulin therapy and healthcare services among Japanese insulin initiators during their first year: a descriptive analysis of administrative hospital data
S. Ikeda (2015)
Insulin regimens and glycemic control in different parts of Europe over 4years after starting insulin in people with type 2 diabetes: Data from the CREDIT non-interventional study.
L. Blonde (2017)
Première année de suivi des patients diabétiques de type 2 mis sous insuline en vie réelle (étude CREDIT-France)
B. Balkau (2014)
Unmet Needs in the Management of Type 2 Diabetes Mellitus Patients Starting Insulin Therapy with Basal or Premix Insulin in Routine Clinical Practice in Serbia
T. B. Beljić Živković (2018)
Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus
N. Inagaki (2016)
Which oral antidiabetic drug to combine with metformin to minimize the risk of hypoglycemia when initiating basal insulin?: A randomized controlled trial of a DPP4 inhibitor versus insulin secretagogues.
J. Gautier (2016)